Warner Chilcott Plc Ord Cl A Ire: (NASD: WCRX)

$18.92

0.01 (0.05%)

Volume 13,369,537

May 14 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		18.35 - 19.33
	
		52wk Low - High
		10.85 - 22.11
	
		Previous Close
		18.91
	
		Avg. Volume
		6,476,540
	
		Industry
		MED-DRUGS
	
		Market Cap
		4.74 B
	
		Div - Yield
		0.50 - 2.64
	
		Beta
		1.03
	
		PE (Forward)
		5.72
	
		Current Year Est.
		3.31
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		93 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 03/18/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            5.72
                        
                            PEG Ratio
                            1.31
                        
                            Current Year Est.
                            3.31
                        
                            Current Quarter Estimate
                            0.84
                        
                            Most Accurate Estimate
                            0.84
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-09-2013
                        
                            EPS Last Year
                            3.82
                        
                            Expected Earnings Growth
                            4.37%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Warner Chilcott PLC, formerly Warner Chilcott Limited, is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceutical market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. The company has established strong franchises in women's healthcare and dermatology through its marketing techniques and specialty sales forces. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. The company is headquartered in Rockaway, New Jersey.   
Full WCRX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
WCRX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.84	0.79	3.30	3.13
Number of Estimates	11	10	10	11
Low Estimate	0.78	0.73	3.25	2.50
High Estimate	0.90	0.84	3.43	NA
Year Ago EPS	1.02	0.98	4.09	3.30
EPS Growth	-18.09%	-19.49%	-19.19%	-5.21%

More WCRX Estimates

Average Earnings Estimates for WCRX

EPS Growth for WCRX

Industry Analysis

Name	Symbol	Previous Close
WARNER CHIL PLC	WCRX	18.91
CATALYST PHARMA	CPRX	0.94
JAZZ PHARMACEUT	JAZZ	58.69
SANTARUS INC	SNTS	20.39
USANA HLTH SCI	USNA	58.19
BIOCRYST PHARMA	BCRX	1.81
CELL THERAPEUT	CTIC	1.19
CUBIST PHARM	CBST	48.77
ELAN CP PLC ADR	ELN	11.61
INFINITY PHARMA	INFI	32.99

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Earnings Beat at Warner Chilcott

May 13, 2013

Positive Data on BioLineRx Treatment

Apr 18, 2013

Good News for Warner Chilcott

Apr 15, 2013

Back to Neutral on Warner Chilcott

Mar 21, 2013

Astellas Launches Betmiga in the UK

Mar 04, 2013

Warner Chilcott Tops in 4Q

Feb 25, 2013

Warner Chilcott Provides 2013 View

Feb 11, 2013

FDA Nod for Warner Chilcott Drug

Feb 08, 2013

More WCRX Zacks Commentary

Financials

EPS TTM	3.82
Sales	2,541
Net Income	403
Price/Earnings	4.95
Price/Book	NA
Price/Cash Flow	2.96
Price/Sales	1.93

More WCRX Financials

News

Actavis Makes Announcement Under Irish Takeover Rules - Benzinga

May 14, 2013

Benzinga`s M&A Chatter for Tuesday May 14, 2013 - Benzinga

May 14, 2013

Fitch: Strategic Actavis/Warner Combo Could Pressure Credit - Businesswire

May 14, 2013

Volume Spike Detected in Shares of Warner Chilcott as They Move Higher on 1.7x Above-Average Volume (WCRX) - Financial News Network Online - Unusual Volume

May 14, 2013

Announcement Under Irish Takeover Rules Relevant Securities in Issue - Globenewswire

May 13, 2013

Market Maker Surveillance Report. TIVO, HCBK, WCRX, BRCD, NVDA, ZNGA, Bullishly Biased Price Friction For Friday, May 10th 2013 - M2

May 13, 2013

Stock Investors Bid Up Shares of Warner Chilcott, Up 6.6% - Financial News Network Online - Market Movers

May 13, 2013

Stocks Open Down In Weak Trade; Netflix, Warner Chilcott Rising - Investors Business Daily

May 13, 2013

See All News Stories on WCRX

Broker Recommendations

Current ABR	1.54
ABR (Last Week)	1.59
# of recs in ABR	13
Average Target Price	20.71
Industry Rank by ABR	93 out of 265
Rank in Industry	18 out of 91

More WCRX Broker Recommendations

Day Low - High	18.35 - 19.33
52wk Low - High	10.85 - 22.11
Previous Close	18.91
Avg. Volume	6,476,540
Industry	MED-DRUGS
Market Cap	4.74 B
Div - Yield	0.50 - 2.64
Beta	1.03
PE (Forward)	5.72
Current Year Est.	3.31
Quarterly Earnings ESP	0.00%

PE (Forward)	5.72
PEG Ratio	1.31
Current Year Est.	3.31
Current Quarter Estimate	0.84
Most Accurate Estimate	0.84
Earnings ESP	0.00%
Next Earnings Report Date	08-09-2013
EPS Last Year	3.82
Expected Earnings Growth	4.37%

Username: Password:

Remember me [?]

Warner Chilcott Plc Ord Cl A Ire: (NASD: WCRX)

$18.92

0.01 (0.05%)

Volume 13,369,537

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations